ICIs targeting programmed cell death protein 1 (PD-1) or its ligand (PD-L1) are used to treat cisplatin-ineligible patients with a PD-L1 positive tumor as well as patients that have progressed on first-line platinum-based chemotherapy. The gene discussed is CD274; the disease is neoplasm.